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Depression is frequent in cancerology. Despite its clear im-
pact on patients, it continues to be under-diagnosed and
inadequately treated. There are many reasons for this, rang-
ing from the underestimation of depressive symptoms by cli-
nicians, their widespread presence in the context of cancer,
the entanglement of depressive symptoms with those associ-
ated with the cancer and its treatment, or, indeed, the diffi-
culty of clinicians in exploring emotional symptoms [1,2].
Beyond the fact that depression causes mental suffering that
is not taken into consideration, even though it can be extre-
mely intense in nature, this situation has a major impact on
both morbidity and mortality through a number of different
mechanisms [3,4]:
• Deterioration of quality of life [5].
• Increased sensitivity to pain [6].
• Difficulties observing treatment [7].
• Difficulties communicating with carers, friends and
family.
• Significant burden placed on close relatives [8].
• Increased risk of suicide [9].
• Longer periods of hospitalisation [10].
• Reduced expectation of survival [11].
Depression also results in additional medico-economic
costs, the extent of which we are only just beginning to
understand [12,13].
There is also a risk of over-treatment, with antidepres-
sants being systematically administered for what may only
be an intense feeling of sadness, which may nevertheless be
appropriate in the context and temporary in duration.
2. What is the prevalence of depression in
cancerology?
Although depression is frequently observed in cancerology,
the figures reported by the various related studies differ owingto the variability of the clinical forms of depressive disor-
ders – major depressive episode (MDE), dysthymia,
adjustment disorders with depressed mood, etc. – and the
way in which the diagnosis is performed: clinical interview,
questionnaires or self-report questionnaires which
may be specific to depression (BDI, CES-D and Zung scale)
or more general (HADS, POMS and SCL-90 etc.), variability
of the cut-offs, etc. The figures also vary depending on
the sample and, in particular, on the patient’s medical sta-
tus, type of cancer, location, stage, treatment during or
after cancer, etc. There may also be a bias associated
with the selection of the patients (patients who have agreed
to a clinical psychiatric assessment, convenience sample
etc.).
On average, studies report a prevalence of MDE of 5–10%,
two to three times higher than that in the general population.
In a recent meta-analysis of 70 studies (n = 10,071) conducted
by Mitchell et al. [14], the prevalence of depressions of all
types (ICD, DSM criteria) was 16.3%, with the prevalence of
MDE reaching 6%. The corresponding values rose to 24.6–
29% and 14.3–16.5% in the analysis of 24 studies (n = 4007) of
palliative-phase patients.
The way in which depressive disorders develop during the
period of cancer care is still poorly understood because of a
lack of longitudinal studies.
A depressive episode may be isolated or may have been
preceded by other such episodes. In this latter case, the disor-
der is a recurrent unipolar depression. The patient’s anteced-
ents may also include one or more phases of hypomanic or
manic excitation, or he or she may have presented a hypo-
manic reaction when under antidepressants. In this case, a
bipolar mood disorder is probable. Referral to a psychiatrist
will then be necessary for diagnosis and identification of the
relevant treatment.3. What are the predictive factors?
Some of the risk factors for depression are known and must
be identified at an early stage [15,16].
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• Recent personal history of negative or stressful life events
(bereavement, succession of losses).
• Personal psychiatric antecedents (depression, suicide
attempt, drug addiction and alcoholism) or familial ante-
cedents (depression, suicide attempt and suicide) [17].
• Personality traits – tendency not to express one’s emo-
tions, tendency to consider life events as uncontrollable
and inevitable, low self-esteem and poor emotional sup-
port and tendency to pessimism [18,19].
• Unlike the data obtained in the general population, the
most recent meta-analysis conducted by Mitchell et al.
[14] suggests that gender is not predictive, possibly owing
to the weight of the factors associated with the cancer
itself.
• The role of age (<50 years) remains controversial [14,20].
Social risk factors:
• Being alone (single, divorced, separated and widowed);
• Social isolation [21].
• Low socio-economic status [21].
• Belonging to an ethnic minority [22].
• Perceived lack of social support.
Risk factors associated with the cancerous disease or its
treatment:
• Type of cancer (pancreas, head and neck) [23].
• Advanced stage or metastatic disease.
• Critical phases involving the disclosure of the diagnosis,
disclosure of recurrence or aggravation (metastases) and
palliative care.
• Limitation of treatments.
• Presence of uncontrolled physical symptoms: firstly pain
(RR increased by 2–4 times) [6], as well as nausea, vomiting,
fatigue etc. [24,25].
• Functional handicap and loss of autonomy (neurological
sequelae, stomata and impairment of general condition etc.).
Treatment-related risk factors:
• Immunotherapy – interferon (IFN), interleukin 2 (IL2)
• Long-term corticotherapy [1].
• Certain antipileptics (such as levetiracetam).
• Certain neurotoxic chemotherapies (vinblastine,
procarbazine).
• The thymic toxicity of certain targeted therapies which
cross the hematoencephalic barrier has given rise to a
number of case reports.
• Despite a number of case reports, cohort studies or obser-
vations obtained during double-blind tests have not
revealed any depressogenic impact of tamoxifen [26].
Organic causes:
• Neurological anomalies (primary brain tumour or cerebral
metastases).• Endocrine disorders (hyper- or hypothyroidism, adrenal
insufficiency).
• Metabolic disorders (vitamin B12, folate deficiency).
4. How should depression be diagnosed?
A depressive syndrome is the association of depressive
symptoms that persist over time. The diagnosis of depres-
sion is already a complex affair, even outside of the context
of physical pathology, since it consists in the lasting associ-
ation of a variety of subjective symptoms (at least five, see
below) [27], none of which is specific [28]. In most cases,
these symptoms are difficult to reveal (for example, social
withdrawal that could be explained by cancer treatments),
and the most highly visible symptoms (such as tearfulness)
are the least specific.
In the case of cancer patients, this complexity is further
aggravated by the potentially adapted nature of the depres-
sive emotion in the context of themultiple bereavements that
accompany cancer. One important area will therefore be to
differentiate between ‘normal’ sadness, on the one hand,
and adjustment disorders or depressive episode on the other.
For depression to be diagnosed, it is therefore necessary
for least five symptoms to be present nearly all day for at least
15 consecutive days. In practical terms, the diagnostic ap-
proach should consist of the following steps:
• Use of two simple questions to attempt to identify one of
the major symptoms, namely mental suffering and lack
of interest (absence of desire for anything, affective indif-
ference which can lead to social withdrawal and a loss of
commitment to contact with friends and family) [29].
• If one of these two symptoms is present, identification of
the time criterion – almost every day, almost all day, for
a minimum of 15 days.
• Then attempt to identify associated symptoms (at least
three or four from the list below).
o Feelings of worthlessness or inappropriate guilt (in partic-
ular a painful vision of the past, for example: ‘for my fam-
ily, I’m now nothing more than a burden’, ‘I’ve been a
failure with my children’).
o Recurrent thoughts of death or suicide.
o Significant weight loss or gain (>5% of body weight), or
increase or decrease in appetite.
o Insomnia or hypersomnia.
o Psychomotor agitation or retardation.
o Fatigue or loss of energy.
o Diminished concentration or indecisiveness.
A change in character with the appearance of irritability or
aggressiveness that is inconsistent with earlier behaviour is
also possible.
If five symptoms from the above list, including mental
pain and/or absence of pleasure, are present then the patient
is very probably depressed, and antidepressant treatment is
recommended.
If not, the patient is exhibiting either a temporary depres-
sive reaction (if the criterion of persistence over time is not
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insufficient symptoms are present: for example, sadness on
its own without feelings of worthlessness, sleep disorders or
anhedonia). Antidepressants are not indicated a priori.
Another difficulty affecting the diagnosis of depression is
associated with the distinction between its somatic manifes-
tations (fatigue, anorexia and/or loss of weight, cognitive or
sleep disorders, loss of libido) and the physical symptoms
associated with the cancerous disease or its treatment [30].
A number of ways of overcoming this difficulty have been
described:
• An inclusive approach in which all the symptoms are
taken into account, irrespective of whether or not they
are attributable to the cancer (which clearly leads to a risk
of over-diagnosis).
• An exclusive approach in which the somatic symptoms
are systematically excluded from the diagnostic criteria.
• A substitution method in which these very same somatic
symptoms are replaced by affective substitute symptoms
[31].
When the exclusive and substitution approaches are used,
the risk that the diagnosis may be underestimated is high, in
particular in the case of patients who conceal or repress their
emotions.
In practice, all manifestations that are not clearly linked to
another cause (physical or iatrogenic causes) should be con-
sidered as contributing to the diagnosis of the depressive syn-
drome. The chronology of the disorders is particularly useful
in this context.
It is therefore necessary to pay special attention to the cog-
nitive and affective symptoms that are not directly linked to
the somatic state, together with all their possible nuances:
• Self-devaluation and a painful vision of the past: feelings
of uselessness, worthlessness and guilt (invasive,
generalised).
• Loss of interest and pleasure: affective anaesthesia,
indifference.
• Feeling of worthlessness coupled with feelings of helpless-
ness and hopelessness.
• Desire for death and thoughts of suicide must be system-
atically explored; far from inducing suicidal behaviour,
putting such ideas into words is an opportunity for the
patient to become aware of their pathological nature and
their link, not to a rational perception of reality, but to
his or her own depressive suffering.
• Pathological pessimism.
A final difficulty lies in the fact that patients rarely sponta-
neously express those depressive symptoms that are primar-
ily purely affective in nature (emotional withdrawal, for
example), and that depressive symptoms themselves
(psychomotor retardation, social withdrawal and shame)
and lack of knowledge or minimisation of depressive symp-
toms lower this expression. Simple, open questions should
therefore be favoured during the interview (‘How’s your
mood? And everyday life? Are there some good times? etc.’).It is important to avoid moralizing phraseology (‘face up to’,
‘keep going’) and closed questions (‘Are you in a good mood?
Are you coping?’) which risk blocking the expression of the
experienced feelings and increasing the sensation of guilt
due the patient’s perception of his or her depressed state.
The availability of the carer, whether verbal or non-verbal,
is vital for facilitating emotional expression.
The diagnosis must take into account the time of the
assessment. The assessment of depressive symptoms is diffi-
cult during the days immediately following the announce-
ment of bad news or in the case of an evolutive,
uncontrolled somatic symptomatology, in particular if this
is associated with the experience of pain. In such cases, the
patient should be reassessed at a distance or after the symp-
toms have been treated.
Finally, the idea of a break with earlier behaviour is also
important. The clinician must remain attentive to changes
in the patient’s functioning, whether this is revealed by the
patient or his or her friends and family. Helping patients be-
come aware of this change may also make it easier for them
to grasp the pathological nature of their condition.5. How to screen for depression in cancerology?
Simple, validated tools can be used, and the aim for screening
purposes is to select short tools taking no more than 5 min to
complete. A recent review of the various potential tools for
the screening of distress undertaken by Mitchell [32,33] iden-
tified 35 short tools for the screening of depression, consisting
of 1–14 items. Although some of these specifically assess
depression and have been validated for use in cancerology,
most of them were not specifically designed for administra-
tion to patients suffering from a somatic pathology. This fact
can be problematic when the deterioration of the patient’s
general condition aggravates scores on items that evaluate
the respondent’s somatic state; this criticism has been made
with regard to the BDI (Beck Depression Inventory), for exam-
ple [34]. Others, such as HADS (Hospital Anxiety and Depres-
sion Scale), assess emotional distress at a more general level
but have the advantage of excluding somatic items. The fol-
lowing tools have been validated for use with cancer patients:
single verbal item, PHQ1, PHQ2 (and PHQ2 + help question),
two verbal items BCFD (Bried Case Find for Depression),
Edinburgh Postnatal Depression Scale (EPDS, and Brief EPDS),
Hornheide Screening Instrument (and Hornheide Short
Form), General Health Questionnaire 9, BDI Short Form, HADS
(and HADS depression subscale).
The sensitivity and specificity of the different scales vary
as a function of the cut-offs used and of the patient clinical
condition. None of the tools used today can be claimed to
be irrefutably preferable to any other. It should nevertheless
be noted that in most studies the sensitivity and specificity
of ultra-short tools (consisting of just one or two questions,
‘low mood’ and ‘loss of interest or pleasure’) have been found
to be at least as good as those of longer tools. In the meta-
analysis of screening and case-finding tools for depression
in cancer conducted by the Depression in Cancer Care con-
sensus group [29], 56 diagnostic validity studies (n = 10,009)
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questions and the BDI-II all had level 2 evidence. For screen-
ing, two stem questions had level 1b evidence. As they are
highly acceptable, the stem questions are thus recommended
(grade B recommendation). For every 100 people screened, the
two questions would accurately detect 18 cases in advanced
cancer settings (one missed and seven falsely identified),
and 17 in non-palliative settings (two missed, and 11 falsely
identified as cases).
By contrast, clinical appraisals that are not guided by at
least one or two questions are not recommended, in particu-
lar if the clinicians are not trained [35].
In practice, it is important to remember that the diagnosis
of depression is too complex for any screening tool, used in
isolation, to be able to provide absolute certainty. Neverthe-
less, their use is recommended and can be incorporated with-
in a more global assessment of the patient’s symptoms (as in
the case of the Edmonton Symptom Assessment System,
ESAS), supportive care needs or expectations [32]. The main
value of these tools – and in particular of those which permit
an assessment based on two questions – is that they make it
possible to identify with a high degree of certainty those pa-
tients who are not depressed, and consequently focus the ef-
forts of the oncologist, carer or psychologist/psychiatrist on
obtaining a more in-depth assessment of those individuals
who have screened positively.
However, systematic screening for depression has not as
yet proved its effectiveness in significantly improving pa-
tients’ psychological outcomes [36]. Far from casting doubt
on its usefulness, this fact emphasises the vital need to in-
clude this type of screening in an overall treatment process
that extends through to the proposal and acceptance of
appropriate pharmacological and/or psychotherapeutic
care.6. Depression and the risk of suicide
Despite the variability that can be found in the literature, ow-
ing to problems of both methodology and definition, it is pos-
sible to estimate the risk of suicide in the oncological context
at 1.95–2.8 times higher than in the general population [9,37].
The wish to die is present in 17% of patients in an advanced
phase of cancer.
Certain suicide risk factors are known [20,37]
• Poorly controlled symptoms (pain, fatigue, etc.).
• Masculine gender (relative risk of 1.7 in men and 1.4 in
women compared with the general population [38]).
• Disclosure phase (first year following the diagnosis) [37].
• Site of the tumour (head and neck, lung, gastrointestinal,
brain tumours [9]).
• Existence of a psychopathological disorder (depression,
hopelessness, delirium).
• Familial antecedents of suicide and/or psychiatric illness,
previous personal suicide attempts.
• Pathological impulsivity (personality disorder).
• Substance abuse (alcohol etc.).
• Recent loss (bereavement, for example).• Situation of hopelessness, loss of control or
autonomy [1].
It is interesting to note that most of these factors are found
in cases where patients ask to accelerate their death (hasten-
ing death requests are associated at a significant level with
depressive states, hopelessness, low level of social support,
very poor physical condition and a lower level of recourse to
spirituality) [1]. Whenever patients make this type of request,
one should systematically and carefully search for an emo-
tional disorder that may indicate pathological suicidal
ideation.7. Treatment plan and overall patient care
The treatment of depression has to start at an early stage [39].
It can take a long time to make patients aware of the psycho-
logical nature of their difficulties, encourage them to request
a psychological consultation or to accept the prescription of
psychotropic or, in particular, antidepressant medicaments.
The more intense the psychological distress the longer this
delay may be. It is the systematic attention paid by clinicians
to their patients’ psychological states that permits early diag-
noses and the effective elaboration of an appropriate treat-
ment plan.
The treatment of depression must form part of an overall
care context. First of all, it is necessary to take account of
the patient’s somatic condition, the associated symptoms
and any comorbidities that may be present (pain, fatigue
and sexual problems). It is not possible, for example, to treat
depression in patients with uncontrolled pain [40].
To start from the patients’ expectations – for example, by
identifying with them the symptom that causes them the
greatest distress, or discussing what they can expect from
treatment – may help them to accept depression treatment.
Certain patients, for example, who can no longer them-
selves perceive the loss of the ability to experience pleasure
or are unaware of their psychomotor retardation, may pri-
marily complain of sleep-related problems. An initial pre-
scription of drugs that are effective in combating these
sleep disorders will encourage subsequent adherence to
therapy. The patient’s habitual mode of psychological func-
tioning may also help the clinician guide him or her towards
appropriate psychotherapeutic support. It is also necessary
to try to identify the representations associated with
depression, antidepressant treatments or psychotherapies,
together with any possible prior intolerance of antidepres-
sant treatment.
Patients must be given information about their socio-pro-
fessional circumstances and psychosocial resources (family,
work and environment). What psychosocial resources can
they count on in their family or professional environments?
And, conversely, what strains or obligations are imposed on
them?
The next step is to check the level of information that pa-
tients possess regarding the cancer for which they are being
treated, their understanding of the treatment plan and their
adherence to it. The quality of the cooperation between the
Table 1 – Families of antidepressants.
Family
SNRI : Venlafaxine, minalcipran and duloxetine
Nassa : Mianserine and mirtazapine
Melatonihergic : Agomelatine
Others : Tianeptine
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oncologist, on the other, may if necessary make it possible
to revisit any information that has been inadequately
understood.
Finally, therapeutic care for mental distress, in particular
when drug-based treatments are used, must always be initi-
ated by a stage during which the psychological nature of the
disorders is explained and clear information about the pre-
scribed psychotropic drug – its purpose and any possible side
effects (risk of dependence associated with benzodiazepines
or hypnotic substances, for example) – is provided. Neverthe-
less, given the specific symptoms that characterise depressive
states, it can sometimes be difficult to secure the commit-
ment of depressed patients to a course of treatment, in partic-
ular when they find it difficult to acknowledge the
pathological nature of their condition or when the loss of
hope or confidence in the future is significant. Memory and
attention disorders may aggravate a patient’s reluctance to
agree to psychotropic treatment and impair compliance with
it, especially given that the anxiety that is frequently felt at
the start of treatment may be associated with an increase in
the real or feared side effects.
The discussion of the diagnosis is therefore the first step in
the administration of treatment. The information provided to
depressed patients enables them to better understand the
nature of their distress and retain their independence. The
empathy shown by carers in response to their psychological
distress also constitutes an initial vital and beneficial experi-
ence for depressed patients, who often feel isolated due to the
shame and guilt they experience (and withdraw themselves
both from their friends and family and from their oncological
team) [41].
To treat major depressive episodes it is necessary to pre-
scribe both an antidepressant and, in certain cases, a course
of psychotherapeutic care [1,15] or, at the very least, to ensure
the availability of psychosocial support to facilitate adherence
to treatment [42].8. When and how to prescribe an
antidepressant?
It is appropriate to prescribe an antidepressant for all major
depressive episodes. This prescription does not always have
to be accompanied by treatment by a psychiatrist except in
the case of depression affecting patients with bipolar mood
disorders who should be referred to a psychologist for diagno-
sis and treatment. In a recent Cochrane review [43] it was
established that antidepressants outperform placebo level
among patients with somatic diseases (OR 2.33, IC 1.8–3,
P < 0.00001). This finding redresses a scientific shortcoming
in the field of cancerology: in 2008, only 20 studies of the
effectiveness of antidepressants had been conducted in this
field and none of them had reached a sufficient level of proof
[2]. However, we still need to gain a better understanding of
the rationale underlying the pathogenesis of depression in
the cancer field and, in particular, its links with the immune
and inflammatory mechanisms.A preventive treatment is not recommended except in
some very specific cases, as in e.g. depression induced by
high-dose interferon alpha [44].
Generally speaking, SRIs (serotonin reuptake inhibitors)
(Table 1) tend to be the first drugs to be prescribed in the field
of cancerology [45]. There is no reason to consider the effec-
tiveness of any antidepressant to be formally superior to that
of any other [46–48]. When administered at antidepressant
dosage (which is considerably higher than the antalgic dos-
age), tricyclics (Table 1) are difficult to handle and should be
reserved for more complex cases. Escitalopram might be the
medicament with the best effectiveness-to-tolerance ratio
among patients who have no contraindication for this drug
[45]. Furthermore, the choice of an antidepressant is specific
to the patient and is determined by individual factors: the
side effects of the drug, the patient’s tolerance to it (which in-
cludes potential side effects in combination with other drugs
being co-administered or that might be used in the future),
reactions to earlier treatments, and the patient’s preferences
[49]. In particular, it is especially important to make sure that
no potential iatrogenics exacerbate the somatic or non-so-
matic difficulties that are already present (for example, sexual
difficulties or asthenia).
In the majority of cases, monotherapy is the rule; to com-
bine two antidepressants is a priori pointless and potentially
dangerous. Although exceptions exist, such prescriptions
should only be made by specialists. Accompanying prescrip-
tions – for example of anxiolytic or hypnotic drugs – should
be restricted. These may be prescribed at the start of treat-
ment but clinicians should attempt to reduce or eliminate
them as treatment progresses.
The fact that a period of 2–3 weeks is required before any
effect can be observed must be explained to the patient
who must also be alerted to the possibility of undesirable side
effects. It is important to remain vigilant with regard to the
aggravated vulnerability of cancer patients (specific metabolic
characteristics, associated treatments) and remain attentive
to the identification of secondary effects which sometimes
may not be easy to detect in a somatic context. Tolerance to
antidepressants varies depending on the drug in question,
and tolerance to tricyclic antidepressants is often poor since
these drugs frequently produce side effects (orthostatic
hypertension, weight gain, sedation, irregular heartbeat, con-
fusion, epilepsy and potentially fatal in the event of an over-
dose), which is why they are not administered as the first
line of treatment. The toxicity of serotonin reuptake inhibi-
tors is less serious and is often restricted to self-limiting dis-
orders (headaches, gastrointestinal disorders). All drugs may
also lead to an increase in anxiety. Venlafaxine and duloxe-
tine have also been reported to lead to increased blood
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gain and drowsiness, two effects that can lead to resistance,
particularly on the part of female patients at the end of the
period of treatment who are already exposed to weight gain
owing to other mechanisms.
There are no restrictions relating to prescriptions for pa-
tients with suicidal thoughts. According to the review con-
ducted by Mo¨ller [50], the risk that such patients will
actually take their own lives under the influence of antide-
pressants appears to be small and decreases from the age of
30 years onwards. If possible, patients who express suicidal
thoughts should rapidly be sent for psychological or
psychiatric assessment. However, if these thoughts are asso-
ciated with depression, this referral should not cause any de-
lay to treatment. A drug with only a low stimulant effect (a
pure serotoninergic drug such as citalopram or paroxetine,
but no noradrenergic products) should be preferred and
should only be prescribed for a short initial period (1 week),
after which the patient should be reassessed.
If there is a risk of suicide, the introduction of the antide-
pressant treatment is an emergency, but not such as the orga-
nisation of the care that is to be received. While awaiting the
results of psychiatric assessment, it is necessary to organise
enhanced monitoring of the patient and inform his or her
family of the suicidal risk, insofar as professional ethics per-
mit this. Ensuring that the patient is accompanied as much
as possible is an important factor in helping to prevent the
occurrence of suicide.
In all cases, it may be of value to try to limit the patient’s
impulsivity by prescribing a sedative and anxiolytic neurolep-
tic such as cyamemazine (e.g. 25–50 mg/day).
Antidepressants present no carcinogenic risk, at least in
the case of SSRIs and tricyclics [51]. Nevertheless, vigilance
is recommended in the case of the prolonged adminis-
tration (more than 10 years) of serotonin–norepinephrine
reuptake inhibitors (SNRIs), since for these recent products
it has not yet been possible to study the associated long-term
risks.
The risk of serotonin syndrome is also frequently cited.
This takes the form of excessive serotonergic stimulation
which causes motor excitation, hyperreflexia, trembling,
myoclonia and dysfunctioning of the autonomous central
nervous system and, in extreme cases, epilepsy, comas or
death. These effects are not due to any idiopathic effect but
are caused by the interaction of drugs sharing similar mech-
anisms or by overdoses [52]. It is extremely difficult to state
their frequency since minor forms are probably not recogni-
sed and still less often reported [52].
Although a treatment can start to have an effect as of the
first few days following prescription, it cannot be viewed as
ineffective until 3–4 weeks of administration at an effective
dosage level (6 weeks in the case of elderly subjects). The
effective dosage can sometimes vary considerably (by a factor
of 1–3 or even 1–4), which means that in the case of lack of
efficacy it is necessary, providing that the patient tolerates
the drug without difficulty, to progressively increase the
dosage before moving on to a new drug. If a drug appears to
be ineffective, it is also necessary to verify correct adherence(and therefore also tolerance to the correct dosage) on the
part of the patient. The minimum period of treatment is
6 months in order to avoid any premature relapse. Treatment
must not be interrupted suddenly given the risks associated
with withdrawal which, with paroxetine, may appear in less
than 48 hours. If oral administration is impossible, it is gener-
ally possible to replace the prescribed drug with injectable
citalopram, the only SNRI available in this form. If adminis-
tration has to be performed via a tube, then drugs available
in soluble form should be preferred (citalopram, mirtazapine,
fluoxetine and paroxetine).
Table 2 lists the main limitations to prescriptions and con-
traindications. This should be updated by the clinician in the
light of the data available at the time of prescription.
There are also risks of interactions with other drugs or of
overdoses. Serotonin reuptake inhibitors are Cyt P450 sub-
strates and may accumulate in individuals with slow metab-
olism or if Cyt P450 is inhibited. The SNRIs are also CytP450
inhibitors whose effect varies from drug to drug (in contact
with different isoenzymes). There is therefore a risk of inter-
action. This is due as much to the accumulation of the sub-
strate as to its ineffectiveness when in the form of an
inactive prodrug. The important thing is to be aware of the
possibility of interactions and to be vigilant [53]. Several inter-
net sites provide regularly updated information that can be
consulted if required.
Although the prescription of psychostimulant drugs (pri-
marily methylphenidate or modafinil) may be considered in
the case of depressed patients (but in most countries remains
outside the scope of marketing authorisation), this should be
done only following a specialist assessment; in any case,
these products are nowadays subject to an initial psychiatric
prescription. Their stimulant effect on vigilance and attention
may be of particular value in cases of asthenia associated
with the prescription of opiates to overcome pain. In some
studies, these drugs have exhibited a rapid antidepressant ef-
fect which can be of value, in particular when the end of life is
near at hand and the period of action required by antidepres-
sants is therefore unacceptable or in order to obtain an imme-
diate effect during this end-of-life period. However, high-
quality studies, in particular involving adequate sample sizes,
are still required in this area. Such psychostimulants should
be prescribed only to patients for whom the experience of fa-
tigue and the functional constraints that this imposes are per-
ceived as an additional source of stress or an intolerable
limitation to their quality of life. Their prescription should
never be influenced by a desire for increased performance,
in particular when made by friends and family distressed by
the patient’s waning enthusiasm and drive and who would
be reassured to see him or her recover the roles which he is
no longer able to assume.
9. Is it necessary to prescribe a benzo-
diazepine?
These drugs should not be prescribed systematically. In prac-
tical terms, it is justifiable to prescribe a benzodiazepine or
anxiolytic:
Table 2 – Main limitations to antidepressant prescriptions and contraindications.
Moderate renal or hepatic insufficiency SSRI, generally not contraindicated; use
the minimum effective dose and start off with half this dose
Severe hepatic insufficiency Use tianeptine or minalcipran
Conduction disorders Avoid tricyclics
Extension of QT, or co-prescription with
drugs associated with this risk
Avoid SNRIs
Cardiac disorders in general Prefer mianserine
Hyponatremia Risk of aggravation in response to SNRIs: monitor
Convulsions or risk of convulsions
(cerebral metastases)
without anticonvulsive treatment
Only tianeptine does not reduce the threshold of epileptogenesis
Arterial hypertension Avoid venlafaxine
Prostatic adenoma Tricyclics are contraindicated. Caution is necessary
with minalcipran and mirtazapine, SNRIs authorised
but possibility of urination difficulties
Administration of tamoxifen Paroxetine and fluoxetine are contraindicated.
SSRI : selective serotonin reuptake inhibitors.
E J C S U P P L E M E N T S 1 1 ( 2 0 1 3 ) 2 0 5 –2 1 5 211• In the presence of a high level of anxiety, in particular in
combination with somatic symptoms which might result
in the poor tolerance of antidepressants (attribution to
the drug of functional symptoms caused or exacerbated
by anxiety).
• If the patient is already being treated with a benzodiaze-
pine – this may subsequently be interrupted; however,
stopping it straight awaymay aggravate the clinical picture
because of drug withdrawal (which, once again, risks being
incorrectly attributed to poor tolerance of the
antidepressant).
In depressed, impulsive patients it is often preferable to
treat anxiety with low doses of a sedative neuroleptic (e.g.
cyamemazine) rather than with a benzodiazepine.10. What are the roles of the different actors in
diagnosing and caring for depression in the field
of cancerology?
Various organisational schemas for care administration in re-
sponse to depressive disorders have been evaluated as a
function of the actors responsible for screening, diagnosing
or prescribing treatment [54].
It is not essential for the initial prescription to be made
by a psychiatrist, in particular given the facts that there
are not enough psychiatrists to provide care to all depressed
patients, and that some of these patients are reluctant to
consult a mental health specialist. Systematic screening fol-
lowed by the diagnosis and the prescription of treatment by
the oncological team itself appears to be the most efficient
way of providing effective treatment [42] if it includes the
arrangement of – at the very least – support services (coor-
dinating nurse, possibly communicating by telephone etc.)
or other psychotherapeutic services. A psychiatrist may as-
sist in the task of prescribing in the most complex cases.
This approach has been validated in North America andseems to be suitable for use in the European context. It al-
lows issue of an initial prescription without waiting for
the psychiatrist, and emphasises the value, in addition
to the prescribed antidepressant [1], of providing to the
patient individual support by a psychologist or a non-
psychologist.
It is advisable to obtain a psychiatric opinion from the out-
set in the case of patients with schizophrenia, a unipolar or
bipolar mood disorder (manic-depressive disorder), a severe
personality disorder or suicidal thoughts.
A psychiatric opinion should also be sought as a second
line of treatment in the event of resistance to treatment even
after an increase in dose, or in the case of any doubt concern-
ing the diagnosis.
Even in the absence of a psychiatric opinion, the question
of hospitalising the patient should be discussed if there is a
risk of suicide or, in the case of refusal of treatment, agitation,
extreme anxiety or delirium. It might also be considered in
the case of extremely isolated patients.
All authors have emphasised the value of offering psy-
chological support to patients, either in the form of psycho-
social support or in the form of psychotherapy. In major
depressive disorders, combining the administration of an
antidepressant with the provision of psychotherapeutic care
improves the effectiveness of treatment. In a meta-analysis
of depression in a non-cancerological environment
(n = 1843), patients treated with a combination of psycho-
therapy (of all types) and antidepressants exhibited a consid-
erably higher level of improvement than patients treated
with drugs only (OR 1.86, 95%CI 1.38–2.52). Furthermore,
the beneficial effect of this combination increased in the
case of treatments lasting for 3 months or longer (OR 2.21,
95%CI, 1.22–4.03) [55]. In this context, initial prescription by
a psychiatrist would be ideal in order to improve the diagno-
sis and ensure, from the outset, that the prescription forms
part of a coordinated therapeutic approach, possibly accom-
panied by a psychotherapeutic element [56]. However, this
solution is only rarely available.
Fig. 1 – Summary of the main stages during diagnosis and the prescription of an antidepressant.
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sometimes in combination:
• Psychoeducation.
• Relaxation training.
• Problem-solving therapies.
• Cognitive behavioural therapies.
• Interpersonal therapies.
• Supportive expressive therapy.
The degree to which these therapies have been validated is
sometimes limited and, in both psycho-oncology and psychi-
atry, the question of the evaluation of psychotherapies and
psychosocial interventions continues to be a complex subject.
The differing natures of the cancer patients, the approachesand therapeutic goals, the training and experience of the ther-
apists, and the multiplicity of assessment scales, as well as
the different periods studied during the health care circuit,
all further complicate such analyses and relativise the results
[57–59]. In this field, the very idea of randomised trials can be
called into question [60] since they do not make it possible to
appraise the subtle effects and individual benefits brought
about by psychotherapy.
Beyond the above reservations, it is accepted that psycho-
therapies have a beneficial impact on anxiety, depression,
psychological distress and quality of life [61,62]. Although it
also seems to be the most depressed patients who gain the
greatest benefits [63,64], this is at the same time the popula-
tion for which the lowest level of evidence is available in
the field of cancerology (only three well-conducted studies
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ive–expressive therapies) [65].
It is important to identify the psychotherapeutic technique
that is best suited for each patient as a function of their per-
sonality, their expressive capacities, their psychosocial situa-
tion, their concern for others and the time at which
oncological care is administered. Thus, patients at the start
of treatment might more readily accept a cognitive or psy-
cho-educational approach, whereas those suffering from a
recurrence of the disease or confronted with a serious devel-
opment in its course might request a more existential form of
psychotherapeutic support. Psychotherapies inspired by psy-
choanalytical and/or psychocorporal techniques could ideally
be offered to all patients who request them provided that
their psychotherapists are able, during preliminary inter-
views, to assess their ability to commit themselves to such
activities and benefit from them.
Fig. 1 summarises the main stages during diagnosis and
the prescription of an antidepressant.11. Conclusion
Depression remains highly prevalent in cancer patients, and
appears to have a great impact on their quality of life as well
as on certain cancer outcomes, even if probably by the means
of its impact on compliance, physical activity, social support
etc. This broad impact justifies carrying out systematic
screening that can be performed by standardised tools but
also by one or two simple questions. To be useful, this screen-
ing must be followed by an adequate clinical diagnosis that
relies on a precise identification of emotional and cognitive
symptoms of depression. Considering the prevalence of de-
pressed patients, the oncological teams are expected to do
the depression diagnosis and make the first antidepressants
prescription by themselves.
To be efficient, depression care must be part of a compre-
hensive care plan, including treatment of somatic symptoms,
and an adequate response to information needs and unmet
needs. When possible, and if accepted by the patient, the help
of a psychologist is highly appreciated. In all cases, patients
should benefit from an accompaniment that can be ensured
by a nurse or a social worker.
More research is still needed on factors that may cause
varying rates of depression and that predict which patients
are mostly at risk. An adequate collaborative care process
ranging from depression screening to effective treatment
has to be implemented and assessed. Longitudinal studies
are still needed to understand the evolution of depressive
symptoms. Randomised controlled trials should also help to
differentiate between the effectiveness of types of psychoso-
cial interventions. Newer antidepressants and stimulants also
should be studied in this population.Conflict of interest
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